Muntean et al. (2025) conducted a systematic review of 16 clinical studies — 730 patients — evaluating hybrid breast reconstruction (HBR): a prosthetic implant combined with autologous lipofilling.
① Overall complication rate: 9% — lower than IBR in comparative studies. ② Immediate lipofilling showed a lower complication rate (8%) than delayed lipofilling (12%). ③ Mean aesthetic satisfaction: 4.4/5. ④ Oncological safety: zero recurrences reported in the included studies.
For LipAge: this study supports plastic surgeons who perform mastectomies and reconstructions as a high-value target audience — and shows that preserved autologous fat has a documented clinical application in this very setting.
Implant-based breast reconstruction (IBR) is currently the most widely used approach after mastectomy. However, its limitations are well known: capsular contracture, upper-pole rippling, compromised skin quality in patients who have undergone irradiation, and dissatisfaction with how natural the result looks.
Autologous lipofilling was introduced to address these limitations. Autologous fat acts through two complementary mechanisms: immediate volume restoration and tissue remodeling mediated by the paracrine effects of the stromal vascular fraction (SVF) — including neoangiogenesis, immunomodulation, and improved skin quality.
Patel et al. (included in the review) directly compared the groups:
• Immediate lipofilling (at the time of implant placement): complication rate of 8% — fewer additional surgeries — reconstruction completed more than 1 year earlier (p < 0.001)
• Delayed lipofilling (a separate procedure): complication rate of 12% — more interventions — longer recovery
Direct implication for LipAge: surgeons who cryopreserve fat at the time of initial collection have high-quality autologous material available for future use upon medical indication — including revision or refinement procedures, without the need for another collection.
No oncological recurrence was reported in the 16 included studies (730 patients, mean follow-up of 20.23 months).
Additional support: Kuruvilla et al. (Ann Plast Surg, 2023) — no increase in recurrence after FG in breast conservation. Tukiama et al. (Eur J Surg Oncol, 2022) — FG in post-mastectomy reconstruction with no adverse oncological impact.
The mean follow-up of 20 months is a genuine limitation — late recurrences (>5 years) are not covered by the available data. Long-term oncological follow-up remains mandatory.
| Title | Exploring the Role of Autologous Fat Grafting in Implant-Based Breast Reconstruction: A Systematic Review |
| Authors | Muntean MV, Pop IC, Ilies RA et al. |
| Journal | Journal of Clinical Medicine (MDPI) |
| Year | 2025 — DOI: 10.3390/jcm14124073 |
| Type | PRISMA systematic review; PubMed + Embase search |
| N | 730 patients; 16 studies; mean follow-up of 20.23 months |
| Relevance to LipAge | High — validates autologous fat in implant-based reconstructive surgery, confirms medium-term oncological safety |